Get started
Author

José‐Francisco Rocha

Observed names: J Rocha, J. Francisco Rocha, J. Rocha, J.-F. Rocha, J.F. Rocha, J.‐F. Rocha, JOSE-FRANCISCO ROCHA, Jose-Francisco Rocha, José Francisco Rocha, José-Francisco Rocha, José-Francisco. Rocha
Institution: Bial (Portugal)
Observed institutions: Bial (Portugal), University of Lisbon, Innsbruck Medical University, Inserm, Universidade do Porto, Universität Innsbruck, Centre Hospitalier Universitaire de Toulouse, Instituto de Medicina Molecular João Lobo Antunes, Université de Toulouse, University College London
ORCID: 0000-0003-2611-4850
Observed ORCID: 0000-0003-2611-4850
OpenAlex ID: A5071860003
Pharmacokinetic and safety profile oftrans‐resveratrol in a rising multiple‐dose study in healthy volunteers
2009 · Luis Almeida, Manuel Vaz‐da‐Silva, et al. · Molecular Nutrition & Food Research · 441
Opicapone as an adjunct to levodopa in patients with Parkinson's disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial
2015 · Joaquim J Ferreira, Andrew Lees, et al. · The Lancet Neurology · 304
Opicapone as Adjunct to Levodopa Therapy in Patients With Parkinson Disease and Motor Fluctuations
2016 · Andrew J. Lees, Joaquim Ferreira, et al. · JAMA Neurology · 197
Pharmacokinetics of Trans‐resveratrol Following Repeated Administration in Healthy Elderly and Young Subjects
2009 · Teresa Nunes, Luis Almeida, et al. · The Journal of Clinical Pharmacology · 115
Effectiveness and safety of opicapone in Parkinson’s disease patients with motor fluctuations: the OPTIPARK open-label study
2020 · the OPTIPARK investigators, Heinz Reichmann, et al. · Translational Neurodegeneration · 68
PDF
Effect of opicapone and entacapone upon levodopa pharmacokinetics during three daily levodopa administrations
2014 · José-Francisco Rocha, Amílcar Falcão, et al. · European Journal of Clinical Pharmacology · 68
Effect of opicapone on levodopa pharmacokinetics, catechol‐O‐methyltransferase activity and motor fluctuations in patients with Parkinson's disease
2015 · J. J. Ferreira, J.‐F. Rocha, et al. · European Journal of Neurology · 66
Long‐term efficacy of opicapone in fluctuating Parkinson's disease patients: a pooled analysis of data from two phase 3 clinical trials and their open‐label extensions
2019 · J. J. Ferreira, A. Lees, et al. · European Journal of Neurology · 60
PDF
Effectiveness of opicapone and switching from entacapone in fluctuating Parkinson disease
2018 · Joaquim J. Ferreira, Andrew J. Lees, et al. · Neurology · 55
Redefining the strategy for the use of COMT inhibitors in Parkinson’s disease: the role of opicapone
2021 · Peter Jenner, José-Francisco Rocha, et al. · Expert Review of Neurotherapeutics · 53
PDF
Effect of Opicapone on Levodopa Pharmacokinetics in Patients with Fluctuating Parkinson's Disease
2022 · Joaquim J. Ferreira, Werner Poewe, et al. · Movement Disorders · 44
PDF
Safety Profile of Opicapone in the Management of Parkinson’s Disease
2019 · Andrew Lees, Joaquim J. Ferreira, et al. · Journal of Parkinson s Disease · 35
PDF
Safety, Tolerability, and Pharmacokinetics of FAAH Inhibitor BIA 10‐2474: A Double‐Blind, Randomized, Placebo‐Controlled Study in Healthy Volunteers
2021 · José‐Francisco Rocha, Ana Santos, et al. · Clinical Pharmacology & Therapeutics · 32
PDF
Effect of 3 Single‐Dose Regimens of Opicapone on Levodopa Pharmacokinetics, Catechol‐O‐Methyltransferase Activity and Motor Response in Patients With Parkinson Disease
2015 · José‐Francisco Rocha, Joaquim J. Ferreira, et al. · Clinical Pharmacology in Drug Development · 31
Pharmacokinetic interaction study between eslicarbazepine acetate and topiramate in healthy subjects
2010 · Teresa Nunes, Eric Sicard, et al. · Current Medical Research and Opinion · 31
Efficacy and safety of eslicarbazepine acetate as adjunctive therapy for refractory focal-onset seizures in children: A double-blind, randomized, placebo-controlled, parallel-group, multicenter, phase-III clinical trial
2020 · Fenella Kirkham, Stéphane Auvin, et al. · Epilepsy & Behavior · 28
PDF
Pooled efficacy and safety of eslicarbazepine acetate as add‐on treatment in patients with focal‐onset seizures: Data from four double‐blind placebo‐controlled pivotal phase III clinical studies
2017 · Christian Elger, Mathias Koepp, et al. · CNS Neuroscience & Therapeutics · 28
PDF
A Double‐Blind, Randomized, Placebo and Active‐Controlled Study of Nebicapone for the Treatment of Motor Fluctuations in Parkinson's Disease
2010 · Joaquim J. Ferreira, Olivier Rascol, et al. · CNS Neuroscience & Therapeutics · 27
The Parkinson’s Real-World Impact Assessment (PRISM) Study: A European Survey of the Burden of Parkinson’s Disease in Patients and their Carers
2021 · Eduardo Tolosa, Georg Ebersbach, et al. · Journal of Parkinson s Disease · 26
PDF
Effect of eslicarbazepine acetate on the pharmacokinetics of metformin in healthy subjects
2009 · J.-F. Rocha, M. Vaz-da-Silva, et al. · International Journal of Clinical Pharmacology and Therapeutics · 21
The Added Benefit of Opicapone When Used Early in Parkinson's Disease Patients With Levodopa-Induced Motor Fluctuations: A Post-hoc Analysis of BIPARK-I and -II
2021 · José-Francisco Rocha, Georg Ebersbach, et al. · Frontiers in Neurology · 20
Efficacy and safety of opicapone, a new COMT-inhibitor, for the treatment of motor fluctuations in Parkinson's Disease patients: BIPARK-II study
2013 · A. Lees, J.J. Ferreira, et al. · Journal of the Neurological Sciences · 20
Safety, Tolerability and Efficacy of Eslicarbazepine Acetate as Adjunctive Therapy in Patients Aged ≥ 65 Years with Focal Seizures
2018 · Raquel Costa, Bernhard Steinhoff, et al. · Drugs & Aging · 18
PDF
Evaluation of opicapone on cardiac repolarization in a thorough QT/QTc study
2015 · Roberto Pinto, Philippe l'Hostis, et al. · Clinical Pharmacology in Drug Development · 18
Dosage Form Proportionality and Food Effect of the Final Tablet Formulation of Eslicarbazepine Acetate
2008 · Carlos Fontes-Ribeiro, Tice Macedo, et al. · Drugs in R&D · 17
Works count: 69
Citation count: 1,979
H-index: 20
I10-index: 33
Year
Topic
Type